Drug intelligence / Profile preview

TC-N201

Development stage: Phase 2
Lead developer: TCRCure Biotech
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TC-N201 is a T cell receptor (TCR) engineered T cell therapy developed by TCRCure Biopharma Ltd. It consists of autologous T cells that have been genetically modified to express a TCR specifically targeting the cancer-testis antigen New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) when presented by HLA-A2. This therapy is designed to treat advanced solid tumors in patients who express HLA-A2 and are positive for NY-ESO-1, aiming to induce an immune response against cancer cells.

Targets

HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)

Beyond the preview

Go deeper on TC-N201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TC-N201.

Explore the full profile